Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations

BACKGROUND: Aimed to identify the benefit population from continuation of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), this study investigated the efficacy of continuation of EGFR-TKIs plus chemotherapy beyond the response evaluation criteria in solid tumors-progressive d...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Thorac Dis
Hlavní autoři: Ding, Ting, Zhou, Fei, Chen, Xiaoxia, Zhang, Shijia, Liu, Yinan, Sun, Hui, Ren, Shengxiang, Li, Xuefei, Zhao, Chao, Wang, Heyong, Zhou, Caicun
Médium: Artigo
Jazyk:Inglês
Vydáno: AME Publishing Company 2017
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5708402/
https://ncbi.nlm.nih.gov/pubmed/29221264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2017.07.107
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky